| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Restoret | EYE103; EYE-103; MK-3000; ANT-39 | Phase 3 Clinical | Diabetic macular oedema; Macular Degeneration | Details | |
| BI-905681 | BI-905681 | Phase 1 Clinical | Boehringer Ingelheim Ltd | Neoplasms | Details |

BettinastraBe 30, 60325 Frankfurt am Main



